Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Thanks to posters who answered some of my questions on OBD. I read an interesting post on ADVFN - the person questioned why Seneca were off-loading shares in OBD and saying that they may know more than the public know which may be the case, it may be down to Co. rules but I doubt it, why would Seneca throw away profits?
Also I'm still puzzled why mainstream media still not reporting, and as far as I know there's not been coverage in prestigious medical journals - New England Journal of Medicine, Lancet, Annals of Internal Medicine, British Medical Journal, and Journal of the American Medical Association.
I know MM's have been manipulating the share price and still will.
My gut feeling is that if this is so good, there wouldn't be so many questions un-answered.
So I'll hold what I have but not add until the murkiness clears, if it's as good as been mooted the price will soon be in pounds. We are a long way from that.
But good luck to all.
Dibs 61 had an intelligent post saying Seneca might have had to sell because of their trading rules which I accept may be the reason they reduced their holding. But if this is so good and obviously a global winner, why the hell are institutions not buying in big time.
Could it be the Co. is in talks about a takeover by big pharma?
I have questions as to what facilities the Co. has to produce everything required to test en-masse in the US and UK and when are the mass market tests due to start, who will review the results etc. etc.
A roll out in the US and UK is going to cost a shed load, where's the cash?
A detailed RNS about the imminent future plans and how funded is really over due now.
And I still don't get why this is still not mass media news
I'm holding my shares - losing money right now and thinking well this is an AIM share, how many times have I seen the dead certainty just be dead.
No more news gives everyone the jitters...
GLA from nervous nellie :-)
I guess SOLI have an arrangement with ii to send the info to shareholders.
Very long winded but well put together and all looked positive
When the markets get out of their morbidity trough, which they will, SOLI SP should do well imho
It's the general despondency that holds the SP back - unfortunately - again imho
"Pink sheets" is an outdated term used to describe stocks that trade over-the-counter (OTC) rather than on a major U.S. stock exchange. These companies cannot or do not want to meet the requirements for listing on a major U.S. stock exchange like the New York Stock Exchange (NYSE).
People also ask
Is it safe to buy pink sheet stocks?
Many of these stocks tend to be of very small and financially questionable companies, feature wide bid-ask spreads with low liquidity, and are less regulated than large exchanges. Investors should exercise caution and follow their own due diligence before jumping in to trading the OTC markets.
It's OXBOF: but it's a pink sheet share so you can't easily see how it's trading, last price on Bloomberg is $0.14 cents dated Sept. 27th.
Someone said shares were rocketing in the US this morning.
From Simply Wall Street, the following
Risk Checks
We perform automated risk checks on every company. We flag any failed checks as potential investment risks. A company which passes all our checks, however, is not 'risk free'.
Oxford BioDynamics (OXBO.F) Risk Checks
Fail
Are they in a good financial position?
Has less than 1 year of cash runway
Section 4.4
Fail
Is their share price liquid and stable?
Shares are highly illiquid
Share Price
Fail
Have shareholders been diluted over the past year?
Shareholders have been substantially diluted in the past year
Section 7.3
Fail
Are revenue and earnings forecast to grow?
Earnings have declined by 28.8% per year over past 5 years
Section 3.1
Fail
Do they have meaningful levels of revenue?
Makes less than USD$1m in revenue (£289K)
Section 3.1
Fail
Do they have a meaningful market capitalization?
Does not have a meaningful market cap ($75M)
Section 8.0
Pass
Are there any concerning recent events?
No concerning events detected
Share Price
Pass
Do they have sufficient financial data available?
At least 3 years of financial data is available
Section 3.0
Pass
Do they have negative shareholders equity?
OXBO.F does not have negative shareholders equity.
Section 4.2
Pass
Is their dividend sustainable?
They do not pay a dividend
Section 5.0
No data
Are they forecast to achieve profitability?
Insufficient data
Section 2.0
No data
Do they have high quality earnings?
Unprofitable so not applicable
Section 3.1
No data
Have profit margins improved over the past year?
Insufficient data or unprofitable
Section 3.1
No data
Has there been substantial insider selling in the past 3 months?
No 3 month insider trading information
Section 7.1
Not very encouraging.
I'm not de-ramping, I simply want more info before investing big (for me) and I am far from doing that as too many things don't make sense - a typical AIM share it looks like so far.
Could someone post the Times article (it's behind a paywall).
Maybe someone could advise me on how I see current share info in the US (I don't know what a pink sheet share is except that it's illiquid. I will try and find out myself.
Thanks in advance
The Times article is Business news. It's not really mainstream either - Daily Mirror/Express/Daily Mail etc. are. And Radio/TV of course. My point is that the SP would rocket IF it was mainstream news, it's not right now, the news is priced in.
£750 for a test is very pricey in these hard times, that will deter a lot of people here and in the states.
btw the Times is behind a paywall.
I imagine some folk on this board would know press reporters (I don't) I would at least like to know why this isn't mainstream news. I didn't get a PSA test as it was so iffy on results, a waste of time. If this had been around when I was looking I would have paid the £750, I'm not well off but what price life....
A couple of days ago some big bbc coverage on prostate cancer, but nothing about OBD's breakthrough.
I've not seen any in Telegraph or Guardian
If anyone has press contacts, please spread the news...
Maybe there has been some that I haven't seen...
This new bloke, Dr Sargeant's experience seems to be all in the medical side of things rather than hard headed business.
The results are dreadful and pathetic really, turnover about the same value as a 3 bed house in the south east.
All seems very Mickey Mouse when you read the financials from Co. inception to now, pretty much all minus signs.
And yet their website is very professional looking and well put together, their clients seem to like the Co. by giving them more work. But it's all peanuts.
Very dodgy in my opinion, I bought in last week...
I understand - sort of - what they do and how, not sure of their market - how big is their universe for good paying clients and how good is their PR (etc, etc)
I'll keep holding as I bought high when most were probably taking profits...
Not a big holding but Iwon't be pound cost averaging..
GLA
This Co. has got my notice and I've looked at their website but if anyone has some relevant info in layman's terms about them and could paste it here that would be great, things like their competition, why the SP history is so volatile - what caused the drops years ago, it would help me to invest - and others.
GLA Rob
JOHCM: Kooth en route to £100m annual recurring revenue
JOHCM’s Mark Costar tipped digital mental health and wellbeing company Kooth (KOO) to reach £100m annual recurring revenue and said its valuation is way off its potential.
Costar holds the Citywire Elite Company in his £227m JOHCM UK Growth fund and in a recent update noted Kooth’s ‘transformational contract win in California’ after it was awarded a £146m contract with the US state to provide digital mental health services to its six million 13-to-25-year olds.
‘As a reminder, this relative minnow on the UK stock market was selected in a competitive process involving 450 potential providers,’ Costar said.
‘In our opinion, the business is on a pathway to £100m annual recurring revenue in the long-run and a market valuation that still pales compared to its potential.’
Costar also noted that the company ‘raised growth funds at a premium to the prevailing market price’.
The shares retreated 2.6%, or 8.7p, to 320p on Monday.
I'm not an accountant and I always find BUR's accounts the most complicated out of any Co. There seems to be quite a few losses and not much coming in. I pretty well ignore any forward guidance as that's jam tomorrow not today. So far I think the market is unimpressed, but it's early and BUR is a limited market so things may change. Volume at 77 thousand pretty low. I was hoping for much more and ready to invest but I'm finding it all jam tomorrow as usual and so won't be.
Shame!!
I hope the results are good but I have no idea, Covid slowed down massively court judgements and so there's a backlog and I guess there won't be a huge increase to BUR coffers. I think Argentina will eventually pay up but that may be years away after elections and maybe a sensible Govt. It has a lot of resources but still is paying IMF interest (no capital) of 45 billion bailout, they got a recent IMF sum of 4 to 5 billion - but that was used to pay the interest on the 45 billion loan.
So for me it depends on what BUR says on it's other cases and it's overall cash position.
Burford continues to baffle me. While the announcement sounds like good news, it's not rock solid given Argentina's history of not paying debts and their current inflation rate of 105%, thats the highest in 32 years. The last time that happened led to hyperinflation of 5,000%, it's a very poor country and politically unstable (read full page article in this weeks Money week) and so paying out billions of dollars when their exchange rate to the dollar is sliding dramatically, one month ago 1 dollar = 370 pesos, now it's 392 pesos to 1 dollar.
I just can't see them paying up and continue to stall. I wish I had more faith in BUR's other cases but at present I don't.
With Bur it's been jam tomorrow since the MW attack, and MW were correct about a lot, hence Bur HAD to change it's operation. It's going up now - why - it's from a very low base. Over the past 5 years it's lost 60.17% as I write. Google it!
It was 19% down yesterday.
Very glad I got out years ago, I follow it because of the Argentina supposed payout. With Inflation in Argentina at 100+% and their history of defaulting and corruption I don't think BUR stands a chance of getting paid and will be very costly for them to try.
They presented their results without letting UK shareholders know, no warning no news for months.
I'm not sure if they are 'dodgy' or just inept, a bit of both I think
Wish I had loaded up on these a couple of years ago! Bought recently and happy enough.
Anyone got another winner?
I've taken a punt on HVO and all I can see is upside to them, niche market and they are getting a lot of contracts, no debt, expanding etc. Money Week likes them!
Jet2 seems to be flying...
BUR has been a dog since the muddy waters attack, and it seems mgt have learned nothing (IMHO), certainly as far as investors are concerned and of course general PR for the Co.
On ADFN are the die hard cult following BUR analyzing every nuance but it's always jam tomorrow and for 5 years the SP has made a loss. The New York listing has been a loss since inception.
I had a big holding around 2018 and saw the SP to £20+, then MW and it's stayed twixt 600 -800p since.
Even if they get 1 billion over 10 years is that going to move the stock to dizzy heights - I really don't know and will appreciate comments. I worry that Argentina with inflation at 100% (2 weeks ago) and their awful track record will say one thing and do another.
Tils/Accustem - a joke, waste of time